U.S. 3D printer manufacturer 3D Systems has unveiled plans to expand on its bioprinting program after acquiring Volumetric Biotechnologies for $400 million.
Bought for an initial $45 million, with a further $355 million set to be paid upon the completion of application-specific goals, Volumetric Biotechnologies is a developer of 3D bioprinting technologies, that it says are capable of creating bespoke “world-changing” biological structures.
Through its acquisition, 3D Systems aims to leverage the Volumetric team’s expertise to broaden the applications of the ‘Print to Perfusion’ technology it has developed with United Therapeutics. Rather than focusing solely on bioprinting human lung scaffolds, the firm now aims to develop two further organs, as well as vascularized tissues for human non-organ regenerative medicine applications.
“Our work on a vertically-integrated platform for the 3D printing of organ scaffolds followed by cellularization to create fully-compatible human organs, dovetails perfectly with the work being done by 3D Systems and United Therapeutics,” said Volumetric Biotechnologies’ Jordan Miller. “Working together, we expect to accelerate these efforts, expanding them beyond lungs to other human organs.”

A human vasculature model created using 3D Systems’ Print to Perfusion process. Image via United Therapeutics.
Progressing Print to Perfusion
Over the last fifteen months, 3D Systems has undergone a drastic restructuring that has seen it return to growth by refocusing on the profitability of its core industrial and healthcare verticals. In that time, the firm’s strategy has seen it dispense with any subsidiaries that don’t match with its wider ambitions, including the likes of Simbionix, Cimatron, Battery Ventures, and its Quickparts 3D printing bureau.
Using the capital generated by its divestiture drive, the company has since been able to re-invest in the growth of its target healthcare and industrial markets. To bolster its offering in the latter, 3D Systems bought Additive Works during May 2021, a former AM Ventures-backed developer of productivity-boosting simulation-based 3D printing workflow software.
The company has also invested heavily in bioprinting, buying bioprinter developer Allevi to expand on its ability to create in-vivo cellular structures, and it recently announced “tremendous progress” within its Print to Perfusion program as well.
Developed alongside United Therapeutics over the last four years, 3D Systems’ Print to Perfusion platform is designed to 3D print scaffolds, which can be lined with patients’ cells to create viable, personalized human tissues. To date, the companies have mainly focused their efforts on producing functional human respiratory scaffolds, that provide lung disease sufferers with much-needed transplants.
However, following 3D Systems’ prospective acquisition, the firms have now made an amendment to their partnership, which will see them attempt to develop other human organs, and continue working together until at least 2025.
“We are excited to expand our patient-cell-based 3D bioprinting activities into additional organs,” added Martine Rothblatt, CEO of United Therapeutics. “This approach avoids the need for immunosuppression, and thus provides a most hopeful pathway to satisfying the huge unmet medical need for organ transplantation.”

3D Systems has invested heavily in the future growth of its Healthcare division over the last fifteen months. Photo via CBRE Group.
Volumetric’s $400M acquisition
Volumetric was co-founded by Jordan Miller and Bagrat Grigoryan in Houston during 2018, with the stated aim of “empowering the next generation of advanced biofabrication,” with its bioprinting systems and materials. Predominantly designed to address R&D applications, the company sells just a single bioprinter in the form of the Lumen X, which was first brought to market via a partnership with CELLINK.
Using its bioprinting technologies, Volumetric has set out create viable organs, primarily focusing its efforts on vascularized liver structures, generating expertise that 3D Systems will now inherit via its acquisition, while its soon-to-be subsidiary has also developed proprietary materials, that could benefit its ongoing research.
While the sale of Volumetric is not expected to go through until later in Q4 2021, when it does, the deal will only see a $45 million holding payment being made for the firm. The other $355 million is said to depend on the “attainment of significant steps in the demonstration of human applications,” with half of the total $400 million fee agreed being paid in shares.
Once completed, the move will see Miller become Chief Scientist for Regenerative Medicine at 3D Systems, which now aims to establish a ‘world-class research’ facility in Houston. Within his new role, Miller is set to work with 3D Systems and United Therapeutics to advance their lung 3D bioprinting efforts, and expand their technology’s applications into the creation of two new organs, as well as developing treatments for trauma and disease.
The purchase also provides 3D Systems with a means of addressing a growing lab-based demand for bioprinted tissues that support drug discovery applications with its technologies, and according to Hall, the deal “dramatically expands its capacity and capabilities for the development of bioprinted human organs” as well.
“It has always been my dream to develop the capability to manufacture fully-biocompatible human organs to save the lives of millions of people in need around the world,” concluded Miller. “I am honored to work with Chuck Hull and his team and look forward to an exciting future together.”

3D Systems’ acquisition could see it become a major player in the bioprinting market along with the likes of CELLINK. Photo via MatTek.
Inching towards commercialization
3D bioprinting may still be an emerging technology, but given the number of start-ups whose systems continue to test the limits of cellular viability, surely it’s only a matter of time before biofabrication becomes mainstream. One of the growing sector’s largest firms is CELLINK, the 3D bioprinting division of the rebranded BICO group, which announced sales growth of more than 600% in its H1 2021 financials.
Elsewhere, biotechnology firm mimiX Biotherapeutics has launched its proprietary cymatiX acoustic bioprinter, which is capable of using sound waves to fabricate multi-cellular tissue constructs. This ‘Sound Induced Morphogenesis’ technology, is designed to allow research users to overcome the cost and speed drawbacks associated with tissue engineering and regenerative medicine R&D.
In practise, 3D Systems isn’t the only company to have made progress producing organ scaffolds either, as earlier this year, Korean firm T&R Biofab also managed to 3D bioprint viable liver tissues. Produced in the form of ‘lobules,’ similar to those found in the human body, the cells were successfully transplanted into animal test subjects, in a potential step towards future regenerative liver therapies.
https://3dprintingindustry.com/news/3d-systems-to-expand-bioprinting-program-after-buying-volumetric-biotechnologies-for-400m-198608/
Congratulations to our nvestors who invested in spring 2020 and the previous investors of the startup: Boost VC, 500 Startups, ICU Ventures, U Ventures, part of Horizon Capital, and supermodel Natalia Vodianova.
Consumers have shifted most of their spending towards e-commerce. Since April 2020 the startup's revenue has increased by 5.6 times.
Investment funds Almaz Capital, TMT Investments and Zubr Capital entered the $ 6.5M Series A round of the startup 3DLook. The total investment in 3DLook thus reached $ 11.2M, not counting the personal investment at the start.
The capital will be used to expand the company's management in the United States and establish new research laboratories in the United States and Western Europe. The startup is actively strengthening its technology development centers with the best talent from all over the world, no longer limited to just Ukraine.
In 2020, we witnessed the transition of 3DLook from trial and experimental deployments to long-term contracts. 3DLook has over 100 clients worldwide including industry giants Safariland, Fechheimer Brothers, Berkshire Hathaway.
3DLook will be part of the official standards to be released in the coming months because it is a member of the Institute of Electrical and Electronics Engineers' Mobile Body Scanning Standards.
Vadim Rogovskiy: “This round of fundraising will allow us to achieve personalization in a wide range of industries. Our growth strategy includes expanding into other segments, including better tracking health and fitness progress in apps that show how people's bodies develop after exercise. ”
Partnership with Gerber Technology, LVMH, Nvidia, Browzwear, CLO Virtual Fashion, the network of clients around the world and the ambitious plans of the team are paying off to consumers, retailers and investors who financially support the startup.
We are excited to introduce Ali Abussaud, Founding Managing Partner at Hala Ventures, in an interview with Alexander Soroka.
The interview is posted at the VC House Channel youtu.be/dyFmFiFnq3s.
It highlights core activities of the fund, its investment profile, portfolio companies, and the investment team.
Ali describes their investment strategy, their structure in the deals and most promising portfolio companies.
Ali also addresses the huge changes that have taken place in the VC ecosystem in Saudi Arabia and the idea of Entrepreneurship World Cup.
We are excited to introduce Jim Thomas, Partner at Kirenaga Partners: Central Florida Tech Fund, in an interview with Alexander Soroka.
The interview is posted at the VC House Channel youtu.be/JpkyHgnYkdw.
It highlights core activities of the fund, its investment profile, portfolio companies, and the investment team.
Jim describes their investment strategies, their structure in the deals and and why they are investing in startups based in Florida.
Jim also addresses startups in the space industry, e.g. one of their portfolio companies that was co-founded by a female entrepreneur.
We are excited to introduce Bill Reichert, Partner at Garage Technology Ventures, Pegasus Tech Ventures, in an interview with Alexandra Johnson.
The interview is posted at the VC House Channel youtu.be/9CSZfc8Wczg.
It highlights a new Bill’s book “Getting to Wow! Silicon Valley Pitch Secrets for Entrepreneurs” - one of the best books for entrepreneurs - that he co-wrote with Angelika Blendstrup. It is written primarily for tech entrepreneurs.
The big idea behind the book is to make sure that entrepreneurs grab an investors’ attention immediately. Bill gives tips for entrepreneurs for great pitching.
Startup Network Space grants an exclusive opportunity
FOR THE ENTREPRENEURS:
to ask us about the SN Ecosystem
to tell about yourself and your project in order to attract early adopters
encourage investment in your project
to find a partner, assemble a team
to get discounts on services for startups or provide your own;)
to communicate - if you have an idea, business or startup, it is important for you to be among like-minded people
to be up to speed with all events for the entrepreneurs
FOR PROFESSIONALS:
to ask us about the SN Ecosystem
to present yourself and your service
to help with advising business
to conduct training webinars
to announce your courses
to communicate and be among like-minded people
to be up to speed with all events for the professionals
FOR INVESTORS (business angel / Family Offices / VC):
to ask us about the SN Ecosystem
to introduce yourself and share facts from your biography that will help you meet other interesting people in the community
to invest or carry on if you are already doing it successfully
to communicate and be among like-minded people (we have created closed associations VC and IB)
to be up to speed with all events from the world of investment and venture capital
To join: https://login.circle.so/sign_up?request_host=space.startup.network#email